The World Heart Federation (WHF) reported on Tuesday the launch of a global study on cardiovascular disease and COVID-19 to better understand the outcomes and risk factors in COVID hospitalized patients and cardiovascular diseases (CVD).
WHF has launched a series of debates focused on how to unlock behavioural and societal change to beat CVD, which kills 17.9m people every year.
The federation added that the people with COVID-19 and heart disease are among those with the highest risk of death and severe complications. The heart might be adversely affected by the virus even in people without pre-existing conditions and the fear of the virus has led to a sharp decline in hospital visits by heart patients for routine and emergency care.
CVD is reportedly caused by smoking, diabetes, high blood pressure, obesity and air pollution and hence it is vital for governments and communities to regulate and make access to healthcare, healthy foods and a healthy way of life accessible and affordable to all people.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment